Q3 EPS Estimate for Allogene Therapeutics Lifted by Analyst

Key Points

• Zacks Research has increased its Q3 2025 earnings estimate for Allogene Therapeutics to ($0.23) per share from a previous forecast of ($0.24).
• Allogene Therapeutics reported ($0.23) EPS for the last quarter, beating the consensus estimate of ($0.28) by $0.05.
• Price targets for Allogene Therapeutics have been adjusted by various analysts, with Citigroup lowering it from $8.00 to $4.00 while still maintaining a "buy" rating.

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities researchers at Zacks Research boosted their Q3 2025 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a note issued to investors on Wednesday, September 3rd. Zacks Research analyst Team now expects that the company will earn ($0.23) per share for the quarter, up from their prior estimate of ($0.24). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics' FY2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.96) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.24) EPS and FY2027 earnings at ($0.98) EPS.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.05.

A number of other brokerages also recently commented on ALLO. Oppenheimer lowered their price objective on Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating for the company in a research note on Wednesday, May 14th. Royal Bank Of Canada reissued an "outperform" rating and issued a $10.00 price target on shares of Allogene Therapeutics in a research note on Wednesday, May 14th. Citizens Jmp cut Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 14th. Citigroup decreased their price target on Allogene Therapeutics from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Allogene Therapeutics in a research note on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.44.

Allogene Therapeutics Trading Down 0.4%

ALLO traded down $0.01 during trading on Friday, reaching $1.14. 860,763 shares of the company were exchanged, compared to its average volume of 4,299,102. The stock has a market cap of $251.83 million, a P/E ratio of -1.02 and a beta of 0.36. The firm has a 50 day moving average of $1.19 and a 200 day moving average of $1.37. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $3.78.

Institutional Trading of Allogene Therapeutics

Institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Allogene Therapeutics during the first quarter worth $28,000. Caption Management LLC acquired a new stake in shares of Allogene Therapeutics during the fourth quarter worth $32,000. CANADA LIFE ASSURANCE Co raised its position in shares of Allogene Therapeutics by 142.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company's stock worth $35,000 after purchasing an additional 18,314 shares during the period. R Squared Ltd acquired a new stake in shares of Allogene Therapeutics during the second quarter worth $37,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Allogene Therapeutics during the second quarter valued at $37,000. Institutional investors and hedge funds own 83.63% of the company's stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).